Bromide

Bromide

SCHEMBL1279110

Br.CCN1CCN(S(=O)(=O)c2cc(C#N)ccc2Oc2cc(C)cc(C)c2)CC1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TBXA2R P21731 9/20 0.43
LMNA P02545 1/20 0.42
KMT2A Q03164 2/20 0.42
USP2 O75604 1/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 2/20 0.41
ALDH1A1 P00352 1/20 0.41
PKM P14618 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1279808 0.99 MAPK1 (0.46) MAPK1HSD17B10TBXA2RLMNAKMT2A
Hydrochloric Acid SCHEMBL1279664 0.98 MAPK1 (0.45) MAPK1HSD17B10TBXA2RLMNAKMT2A
SCHEMBL1279495 0.95 TBXA2R (0.47) MAPK1HSD17B10TBXA2RLMNAKMT2A
SCHEMBL1279869 0.88 CNR1 (0.44) MAPK1HSD17B10TBXA2RLMNAKMT2A
SCHEMBL693683 0.87 TBXA2R (0.45) MAPK1TBXA2RKMT2AUSP2GAA
SCHEMBL693479 0.85 TBXA2R (0.48) TBXA2RLMNAKMT2AUSP2GAA
Sulfuric Acid SCHEMBL1279705 0.85 TBXA2R (0.44) MAPK1HSD17B10TBXA2RLMNAKMT2A
SCHEMBL694163 0.85 TBXA2R (0.45) MAPK1TBXA2RKMT2AGAAALDH1A1
SCHEMBL13108358 0.85 TBXA2R (0.48) TBXA2RKMT2AUSP2GAATSHR
SCHEMBL700275 0.85 KMT2A (0.52) TBXA2RKMT2AUSP2GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088769-A1 SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2012-04-12 US claimed
EP-2627635-A1 SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS Axikin Pharmaceuticals, Inc. (US) 2013-08-21 EP disclosed
WO-2012051090-A1 SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2012-04-19 WO disclosed
US-20120088769-A1 SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088769-A1 SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 MAPK1 317/4885HSD17B10 1836/4885TBXA2R 2996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.